Table 2.
Pharmacodynamic model parameters; effect of respiratory rate on end-tidal carbon dioxide
| Parameters | Estimate (RSE, %) | Median [2.5–97.5%] | ||
|---|---|---|---|---|
| Base model | Final model | |||
| E0, mmHg | 39.8 (0.16) | 39.8 (0.15) | 39.8 [39.7–39.9] | |
| Emax, mmHg | 28.1 (0.87) | 28.1 (0.92) | 28.1 [27.8–28.4] | |
| Ce50, time−1 | 18.1 (3.92)) | Normal | 20.5 (3.48) | 20.3 [19.3–21.4] |
| Antiepileptic drug | 14.9 (6.77) | 15.2 [14.1–16.3] | ||
| γ | 7.6 (5.30) | 7.53 (5.35) | 7.6 [7.2–8.1] | |
| keo, min−1 | 0.47 (8.58) | 0.47 (8.60) | 0.47 [0.42–0.52] | |
| OFV | 1138.8 | 1121.0 (Δ17.8) | ||
E0 = baseline ETCO2 (ETCO2 = 40 mmHg); corrected QT interval in absence of sevoflurane; Emax = maximum decreased ETCO2 (ETCO2 = 30 mmHg); Ce50 = respiratory rate required to achieve 50% of maximum decrease of ETCO2 (ETCO2 = 35 mmHg); ke0 = first-order rate constant determining the efflux from the effect site; γ = slope of sigmoid relation between respiratory rate and ETCO2.